🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block Versus Bupivacaine Alone for Postoperative Pain Management in Patients Undergoing Craniotomy

RecruitingNAAges 18 Years - 65 YearsAllAin Shams University
NCT06993922 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to compare dexmedetomidine as an adjuvant to bupivacaine in scalp block versus bupivacaine alone for postoperative pain management in patients undergoing craniotomy.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age from 18 to 65 years. * Both sexes. * American Society of Anesthesiologists (ASA) physical status I or II. * Undergoing supratentorial elective planned craniotomies. Exclusion Criteria: * Patients refusal. * History of known allergy to the used local anesthetic or dexmedetomidine. * Bleeding disorders. * Evidence of local infection at the site of injection. * Emergency craniotomy. * Psychotic disorder. * Patients who will not be extubated in the operating room after surgery.
💊

What it tests

  • Scalp block
  • Scalp block + Dexmedetomidine
📍

Where

1 site
Ain Shams University
Cairo, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy